Clinical Trial Detail

NCT ID NCT02101788
Title Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

peritoneal carcinoma

ovarian carcinoma

Therapies

Topotecan

Letrozole + Paclitaxel + Pegylated liposomal-doxorubicin + Tamoxifen

Trametinib

Age Groups: adult

No variant requirements are available.